Haupt Dan, Wettermark Björn, Nilsson J Lars G
Department of Health Sciences, Luleå Technical University, Luleå, Sweden.
Pharmacoepidemiol Drug Saf. 2008 May;17(5):461-7. doi: 10.1002/pds.1564.
To explore the possibility of using dispensed volumes asthma/COPD drugs as a proxy for the combined prevalence of asthma plus COPD.
The proportions of the Swedish population with inhalation drugs for asthma/COPD 2004 were obtained using three different databases. A pharmacy record database gave the volumes of dispensed drugs (defined daily doses, DDDs of R03A + R03B drugs) for each patient, 20 years and older. The X-plain database of Apoteket AB gave drug sales data for Sweden and Swedish population data were obtained from Swedish statistics.
The sales volumes of asthma/COPD drugs were much higher for older than for younger people. The volumes increased from 18 DDD/TID for the 20-29 year group up to 124 DDD/TID for patients 70-79 years, or about seven times. The average volumes per patient in the different age groups corresponded to one DDD/day in only three of the age groups (50-79 years). In the youngest group the average drug volume per patient corresponded to one DDD every second day, which may indicate undermedication. The percentages of the Swedish population with asthma/COPD drugs increased from 4.0% for 20-29 years old to 14.5% for 80+ years old, or 3.6 times. When head-to-head comparisons could be made between reported prevalence data of asthma and COPD and our data the two sets of data were in a reasonable agreement.
The prevalence of drug treatment, i.e. the proportion of the population with dispensed asthma/COPD drugs, could function as a proxy for the disease prevalence of asthma plus COPD.
探讨将哮喘/慢性阻塞性肺疾病(COPD)药物的配药量用作哮喘加COPD合并患病率替代指标的可能性。
利用三个不同数据库获取2004年瑞典使用哮喘/COPD吸入药物人群的比例。药房记录数据库提供了20岁及以上每位患者的配药剂量(限定日剂量,R03A + R03B药物的DDD)。Apoteket AB公司的X-plain数据库提供了瑞典的药品销售数据,瑞典人口数据则来自瑞典统计部门。
哮喘/COPD药物的销售量在老年人中比年轻人高得多。销售量从20 - 29岁年龄组的18 DDD/每日三次(TID)增加到70 - 79岁患者的124 DDD/TID,约为七倍。不同年龄组中每位患者的平均剂量仅在三个年龄组(50 - 79岁)中相当于每日1 DDD。在最年轻的组中,每位患者的平均药物剂量相当于每两天1 DDD,这可能表明用药不足。瑞典使用哮喘/COPD药物人群的比例从20 - 29岁的4.0%增加到80岁及以上的14.5%,增长了3.6倍。当可以将哮喘和COPD的报告患病率数据与我们的数据进行直接比较时,两组数据基本一致。
药物治疗的患病率,即配用哮喘/COPD药物人群的比例,可以作为哮喘加COPD疾病患病率的替代指标。